the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Bladder Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
IRB16-0218 O'Donnell, Peter A Phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-pd-L1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy Details
IRB15-0690 Steinberg, Gary A Prospective, Open, Comparative, within Patient Controlled Multicenter Phase III Study of Blue Light Cystoscopy with Cysview and White Light Cystoscopy Using KARL STORZ D-Light C PDD Flexible Videoscope System in Detection of Bladder Cancer in Patients with Bladder Cancer Details
IRB15-0630 O'Donnell, Peter A Phase III, Open-Label, Multicenter, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients with PD-L1-Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy Details
Phase II
Study No PI Title
IRB16-1598 O'Donnell, Peter A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of MOXR0916 In Combination With Atezolizumab Versus Atezolizumab Alone In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma Who Are Ineligible For Cisplatin-Based Therapy
IRB16-0787 O'Donnell, Peter A Phase II Trial of MK3475 in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder Details
IRB16-0255 Steinberg, Gary A Phase Ib/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered with or without Bacille Calmette-Guérin in Patients with High Risk Non Muscle Invasive Bladder Cancer Details
CIRB15-1357 Sharma, Manish EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
IRB15-0703 O'Donnell, Peter A Phase II, Two-Arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations Details
CIRB14-1105 O'Donnell, Peter S1314: A Randomized Phase II Study of Co-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer Details
Phase I
Study No PI Title
IRB16-1743 Ratain, Mark An Open Label Phase I, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies
IRB16-0255 Steinberg, Gary A Phase Ib/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered with or without Bacille Calmette-Guérin in Patients with High Risk Non Muscle Invasive Bladder Cancer Details
IRB15-1767 Luke, Jason A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers Details
IRB15-1544 Steinberg, Gary A Phase Ib, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects with Muscle-Invasive Transitional Cell Carcinoma of the Bladder Details
IRB15-1024 Luke, Jason A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors Details
IRB14-0105 Szmulewitz, Russell A Phase I, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms whose Vasculature Expresses B7-H3 Details
Others
Study No PI Title
IRB16-0355 O'Donnell, Peter UC-GENOME: Urothelial Cancer-GENOmic analysis to iMprove patient outcomes and rEsearch Details
15550B Steinberg, Gary Bladder Cancer Sample Collection
12278A Steinberg, Gary Clinical Urology Research Screening Protocol


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .